Livforsakringsbolaget Skandia Omsesidigt Grows Position in Humana Inc. (NYSE:HUM)

Livforsakringsbolaget Skandia Omsesidigt grew its stake in shares of Humana Inc. (NYSE:HUM) by 2.9% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 4,427 shares of the insurance provider’s stock after buying an additional 124 shares during the period. Livforsakringsbolaget Skandia Omsesidigt’s holdings in Humana were worth $2,029,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of HUM. Cibc World Market Inc. increased its position in Humana by 4.0% during the first quarter. Cibc World Market Inc. now owns 5,709 shares of the insurance provider’s stock worth $2,484,000 after buying an additional 217 shares in the last quarter. Blair William & Co. IL boosted its holdings in shares of Humana by 0.6% during the first quarter. Blair William & Co. IL now owns 5,660 shares of the insurance provider’s stock worth $2,463,000 after purchasing an additional 32 shares during the last quarter. Cetera Investment Advisers boosted its holdings in shares of Humana by 0.5% during the first quarter. Cetera Investment Advisers now owns 4,906 shares of the insurance provider’s stock worth $2,135,000 after purchasing an additional 26 shares during the last quarter. Sequoia Financial Advisors LLC boosted its holdings in shares of Humana by 19.0% during the first quarter. Sequoia Financial Advisors LLC now owns 615 shares of the insurance provider’s stock worth $268,000 after purchasing an additional 98 shares during the last quarter. Finally, Candriam Luxembourg S.C.A. boosted its holdings in Humana by 25.0% in the first quarter. Candriam Luxembourg S.C.A. now owns 29,809 shares of the insurance provider’s stock valued at $12,971,000 after acquiring an additional 5,964 shares during the last quarter. Hedge funds and other institutional investors own 92.38% of the company’s stock.

Insider Buying and Selling at Humana

In other news, Director Jorge S. Mesquita purchased 545 shares of the firm’s stock in a transaction on Tuesday, February 20th. The stock was purchased at an average cost of $367.09 per share, with a total value of $200,064.05. Following the purchase, the director now owns 2,578 shares in the company, valued at approximately $946,358.02. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.32% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

HUM has been the topic of a number of research analyst reports. TheStreet cut Humana from a “b” rating to a “c+” rating in a report on Monday, January 8th. Stephens decreased their target price on Humana from $550.00 to $430.00 and set an “overweight” rating for the company in a research report on Friday, January 26th. UBS Group reaffirmed a “neutral” rating and issued a $370.00 target price (down previously from $530.00) on shares of Humana in a research report on Friday, January 26th. Oppenheimer reaffirmed an “outperform” rating and issued a $630.00 target price on shares of Humana in a research report on Wednesday, January 17th. Finally, Wells Fargo & Company decreased their target price on Humana from $413.00 to $350.00 and set an “overweight” rating for the company in a research report on Monday, April 8th. Eleven analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. According to MarketBeat, Humana has a consensus rating of “Hold” and a consensus price target of $465.42.

Humana Stock Up 2.0 %

NYSE:HUM opened at $330.00 on Thursday. Humana Inc. has a 52 week low of $299.23 and a 52 week high of $541.21. The firm has a market capitalization of $39.81 billion, a PE ratio of 16.32, a price-to-earnings-growth ratio of 1.86 and a beta of 0.45. The stock has a 50 day moving average of $344.41 and a 200-day moving average of $425.71. The company has a current ratio of 1.59, a quick ratio of 1.59 and a debt-to-equity ratio of 0.63.

Humana (NYSE:HUM) last issued its quarterly earnings data on Thursday, January 25th. The insurance provider reported ($0.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.76 by ($0.87). Humana had a return on equity of 19.44% and a net margin of 2.34%. The business had revenue of $26.46 billion during the quarter, compared to the consensus estimate of $25.47 billion. During the same period last year, the company earned $1.62 earnings per share. The business’s quarterly revenue was up 17.9% compared to the same quarter last year. Analysts predict that Humana Inc. will post 16.06 EPS for the current year.

Humana Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, July 26th. Shareholders of record on Friday, June 28th will be paid a dividend of $0.885 per share. This represents a $3.54 dividend on an annualized basis and a yield of 1.07%. Humana’s payout ratio is currently 17.86%.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.